You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):吸入用七氟烷獲得藥品註冊證書
格隆匯 09-29 16:36

格隆匯9月29日丨恆瑞醫藥(600276.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥品註冊證書》。藥品名稱:吸入用七氟烷。

吸入用七氟烷以揮發性氣體的形式從呼吸道通過進入人體內形成麻醉作用,適用於成年人和兒童的全身麻醉的誘導和維持。

吸入用七氟烷由丸石製藥株式會社研發,1990年首次在日本獲批上市,商品名為喜保福寧®,現已在美國、中國、歐洲等國家及地區獲批上市。除公司外,國內另有魯南貝特製藥、河北一品製藥等多家企業的吸入用七氟烷獲批上市,公司此次獲批視同通過仿製藥質量和療效一致性評價。

經查詢,2020年吸入用七氟烷全球銷售額約為7.43億美元。截止目前,吸入用七氟烷相關項目累計已投入研發費用約為1374萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account